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Abstract Urokinase-type plasminogen activator (uPA) binds
with high a⁄nity to its speci¢c cell surface receptor (uPAR)
(CD87) via a well-de¢ned sequence within the N-terminal region
of uPA (uPA1931). Since this uPA/uPAR-interaction plays a
signi¢cant role in tumor cell invasion and metastasis, it has
become an attractive therapeutic target. Two small peptidic
cyclic competitive antagonists of uPA/uPAR-interaction have
been developed, based on the uPAR binding site in uPA:
WX-360 (cyclo21;29[D-Cys21]-uPA2130[S21C;H29C]) and its
norleucine (Nle) derivative WX-360-Nle (cyclo21;29[D-Cys21]-
uPA2130[S21C;K23Nle;H29C]). These peptides display an
only ¢ve to 10-fold lower a⁄nity to uPAR as compared to
the naturally occurring uPAR-ligand uPA. In this study, WX-
360 and WX-360-Nle were tested in nude mice for their potency
to inhibit tumor growth and intraperitoneal spread of lacZ-
tagged human ovarian cancer cells. Intraperitoneal administra-
tion of either cyclic peptide (20 mg peptide/kg; 1U daily for
37 days) into the tumor-bearing nude mice resulted in a signi¢-
cant reduction of tumor weight and spread within the perito-
neum as compared to the untreated control group. This is the
¢rst report demonstrating e¡ective reduction of tumor growth
and spread of human ovarian cancer cells in vivo by small syn-
thetic uPA-derived cyclic peptides competitively interfering with
uPA/uPAR-interaction. Thus, both WX-360 and WX-360-Nle
are promising novel compounds to reduce dissemination of hu-
man ovarian carcinoma. ; 2002 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Introduction
The cellular plasminogen activation system consisting of the
serine protease plasmin, urokinase-type plasminogen activator
(uPA), its speci¢c receptor (uPAR) (CD87) and the two in-
hibitors PAI-1 and PAI-2 plays a signi¢cant role in tumor-
associated processes such as cell proliferation, migration, in-
vasion and metastasis [1^5]. Binding of (pro)-uPA to its cell
surface receptor not only generates a pericellular proteolytic
system, furthermore, surface-associated feedback-activation of
pro-uPA by plasmin results in potentiation of proteolytic ac-
tivity compared to activation in solution [6]. In addition to
this, pro-forms of other proteolytic enzymes such as matrix
metalloproteinases are activated by plasmin as well, allowing
tumor cells to degrade the surrounding extracellular matrix.
This matrix degradation facilitates cell migration and enables
tumor cells to detach from the primary tumor and to spread
to distant loci in the body [1,2,5].
uPA binds with high a⁄nity to its cell surface receptor
uPAR (CD87), via a binding site within the N-terminal re-
gion of the molecule. Previously, we have determined the mini-
mal binding region spanning amino acids 19^31 of uPA and
designed a synthetic cyclic uPA-derived peptide, cyclo-
19;31uPA1931, serving as a lead structure for the development
of small uPA-derived competitive peptide antagonists to in-
terfere with uPA/uPAR-interaction [7]. Initially, we performed
a systematic D-amino acid scan of uPA1931, in which each of
the 13 L-amino acids of the molecule was individually sub-
stituted by the corresponding D-amino acid. This resulted in
the selection of cyclo19;31[D-Cys19]-uPA1931 (WX-307), a po-
tent inhibitor of uPA/uPAR-interaction (IC50W200 nM), dis-
playing only a 20^40-fold lower binding capacity as compared
to the naturally occurring uPAR-ligand uPA [8]. Reduction of
the ring-size and subsequent D-amino acid scanning led to
cyclo21;29[D-Cys21]-uPA2130[S21C;H29C] (WX-360), display-
ing a slightly improved binding to uPAR (IC50W40 nM) as
compared to WX-307 [9,10]. In order to potentially increase
its in vivo stability against proteolytic degradation, the lysine
residue of WX-360 was replaced by norleucine, yielding WX-
360-Nle (cyclo21;29[D-Cys21]-uPA2130[S21C;K23Nle;H29C]).
This cyclic peptide was found to exert similar binding a⁄nities
(IC50W70 nM) than WX-360 [11].
In previous experiments, we have targeted uPAR-expressing
tumor cells in in vivo models by gene transfer of a recombi-
nant soluble form of uPAR (suPAR) as a scavenger for uPA
into human ovarian and breast cancer cells, resulting in high-
level synthesis of this protein [12,13]. In both tumor models,
we observed profound inhibitory e¡ects of suPAR on primary
tumor growth, tumor spread, or experimental metastasis. In
the present study, we investigated whether inhibition of uPA/
uPAR-interaction by small synthetic uPA-derived peptides
represents an alternative strategy to a¡ect primary tumor
growth and metastasis. For this, we inoculated human ovar-
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ian cancer cells OV-MZ-6#8-BAG into the peritoneum of
nude mice, treated the mice with either of the two peptides
WX-360 or WX-360-Nle and analyzed the e¡ects of this treat-
ment on primary tumor growth and spread in vivo.
2. Materials and methods
2.1. Peptides
Two synthetic cyclic peptides have been developed based on the
lead structure WX-307 (cyclo19;31[D-Cys19]-uPA1931) [8], WX-360 (cy-
clo21;29[D-Cys21]-uPA2130[S21C;H29C]) and its derivative WX-360-
Nle (cyclo21;29[D-Cys21]-uPA2130[S21C;K23Nle;H29C]), in which ly-
sine 23 is substituted by norleucine [9^11].
2.2. Cell lines
OV-MZ-6#8 is a clonal cell line derived from the parental cell line
OV-MZ-6, which was originally established from a patient with ad-
vanced serous cystadenocarcinoma of the ovary [14]. OV-MZ-6#8
cells were transfected with the bacterial lacZ gene which codes for
L-galactosidase and, thus, the resulting OV-MZ-6#8-BAG cells can
be stained with the L-galactosidase substrate 5-bromo-4-chloro-3-in-
dolyl L-D-galactoside (X-Gal) in order to follow spreading of tumors
in in vivo models [15]. As tested by ELISA, the lacZ-tagged cell line,
as its parent cell line, expresses both uPAR and uPA. OV-MZ-6#8-
BAG cells were cultured as previously described [16].
2.3. Tumor model
Pathogen-free female athymic (nu/nu) mice (4^6 weeks old), were
obtained from Charles River Laboratories (Sulzfeld, Germany).
3U107 OV-MZ-6#8-BAG cells were suspended in 500 Wl PBS and
inoculated into the peritoneal cavity of nude mice. These mice were
divided into three groups, which either received WX-360, WX-360-Nle
(20 mg/kg/day, respectively), or vehicle only (5% mannitol, 0.6%
DMSO) in a blinded manner. The peptides or the vehicle only were
injected intraperitoneally once per day for 37 days (treatment started
1 day post-inoculation). At the end of the study, the mice were sac-
ri¢ced, all intraperitoneal organs removed and stained with X-Gal [17]
in order to facilitate identi¢cation of the spreading tumor cells. Tumor
weight and total situs weight were measured for evaluation of the
tumor mass as described previously [13]. Finally, the blinded code
was uncovered and statistical analysis performed.
2.4. Statistical analysis
Signi¢cant di¡erences in tumor weight between the groups were
calculated using Student’s t-test owing to normal distribution of the
data. For data on tumor weight over total situs weight, the normal
distribution test was not applicable; therefore, a Kruskal^Wallis one-
way analysis and Dunn’s multiple comparison test were performed to
investigate for di¡erences between the three groups. A signi¢cance
level of 9 0.05 was considered statistically signi¢cant.
3. Results and discussion
Binding of uPA to uPAR supports tumor cell proliferation,
invasion and metastasis. To inhibit this interaction, synthetic
cyclic peptides, derived from the uPAR-binding sequences
within the N-terminal region of uPA (uPA1931), were applied
Fig. 1. Competitive antagonists of uPA/uPAR-interaction. A: Binding of uPA to the tumor cell surface via its cell membrane receptor uPAR
facilitates tumor cell proliferation, invasion and metastasis [5,8]. uPA binds to uPAR by the continuous peptide sequence uPA1931. Based on
this sequence, small cyclic peptidic competitive antagonists of uPA/uPAR-interaction such as WX-360 and WX-360-Nle have been developed
which e⁄ciently block binding of uPA to uPAR [8^11]. B: Structures of WX-360 (cyclo21;29[D-Cys21]-uPA2130[S21C;H29C]) and its norleucine
derivative WX-360-Nle (cyclo21;29[D-Cys21]-uPA2130[S21C;K23Nle;H29C]). The arrows point to the side chain of lysine (K23) in WX-360 and
norleucine (Nle23) in WX-360-Nle, respectively.
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and tested whether such competitive antagonists of uPA/
uPAR-interaction reduce tumor burden of a human ovarian
carcinoma in nude mice (Fig. 1).
After intraperitoneal inoculation of lacZ-tagged OV-MZ-
6#8-BAG cells, mice were treated once per day in a blinded
manner either, with synthetic cyclic peptides (WX-360 or WX-
360-Nle; 20 mg/kg/day) or vehicle until autopsy. After 37 days,
mice were sacri¢ced and all intraperitoneal organs stained
with X-Gal. To describe any therapeutic e¡ect of the di¡erent
peptides, tumor weight over total situs weight was assessed. In
the control group, typically large tumor nodules on the left
peritoneum and beneath the liver (near the site of tumor cell
inoculation), as well as an abundant tumor spread across the
peritoneal muscle layer, mesentery and the diaphragm was
observed. By treating the mice with WX-360 and WX-360-
Nle, fewer and smaller tumor nodules were present than in
the control animals. Often (three of 15 mice in both the WX-
360- and WX-360-Nle-treated groups versus one of 16 mice in
the control group), a larger nodular tumor mass was not even
detectable (Fig. 2). The statistical analysis of the ratios of
tumor weight over total situs weight proved that treatment
of mice carrying human ovarian cancer cells with synthetic
uPA-derived cyclic peptides resulted in a signi¢cant reduction
of tumor burden (WX-360 versus control, P=0.0002; WX-
360-Nle versus control, P=0.023) if compared to the un-
treated control group (Fig. 3A). A trend towards a lower
tumor weight in the WX-360 group was observed. Treatment
of the nude mice by either peptide did not result in serious
side e¡ects during the time of treatment. However, after
1 week, in some mice treated with WX-360-Nle, an obvious
excitability was seen. In addition to the tumor weight, we also
measured organ weights of the mice to assess organotoxic side
e¡ects of the peptides. No signi¢cant di¡erences were ob-
served between all three groups (Fig. 3B), suggesting that
treatment with the peptides did not a¡ect organ growth of
the mice.
A considerable number of studies have already shown that
interference with the plasminogen activation system leads to
reduction of tumor invasion and metastasis. Therefore, this
system with its increased activity in tumor cells represents an
attractive target to attack tumor invasion and metastasis [18].
Various strategies have been employed to reduce the expres-
Fig. 2. Tumor spread of OV-MZ-6#8-BAG cells within the peritoneum. X-Gal-stained organs of mice treated with intraperitoneal injection of
vehicle only (5% mannitol, 0.6% DMSO) (A), WX-360 (B), or WX-360-Nle (C) (37 days; treatment with 20 mg peptide/day/kg; a single injec-
tion per day). At the end of the experiment, in the control group typically a large tumor nodule near the peritoneal inoculation site at the left,
as well as an abundant tumor spread across the peritoneal muscle layer, the mesentery and the diaphragm was observed (A). In the groups of
mice treated with the uPA antagonists, fewer and smaller tumor nodules and strong reduction in tumor cell dissemination was observed (B,C).
Three representative examples of each group are depicted.
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sion of uPA or uPAR or to impair the proteolytic activity,
including the use of synthetic active site inhibitors of uPA as
well as antisense oligodeoxynucleotides or RNA directed
against uPA and uPAR mRNA [3,4,18]. Other concepts are
based on competitive inhibitors of uPA/uPAR-interaction,
which, in fact, also strongly a¡ect experimental tumor inva-
sion and metastasis [18,19]. For example, high-level synthesis
of a suPAR in the vicinity of mammary or ovarian tumor cells
signi¢cantly reduced tumor burden and spread or experimen-
tal metastasis in xenogenic mouse models due to inhibition of
uPA-binding to tumor cell-associated uPAR [12,13]. uPA-de-
rived therapeutic molecules, harboring the uPAR binding site
have also been used frequently in animal experiments; two
di¡erent uPA/IgG chimera (containing either uPA1137 or
uPA148) suppressed the metastatic capacity of human PC3
prostate carcinoma cells and B16 melanoma growth and neo-
vascularization, respectively, in in vivo experiments [20,21].
Furthermore, bifunctional inhibitors encompassing two func-
tionally independent domains, both directed against the uPA/
plasmin system, have been successfully applied in in vivo
models. A hybrid protein, consisting of the receptor-binding
amino-terminal fragment of uPA (ATF), linked to the bovine
pancreas trypsin inhibitor (inhibits plasmin activity also at the
cell surface), strongly inhibited neointima formation and
restenosis [22]. In another set of experiments, a bifunctional
inhibitor encompassing ATF and domain II of the serine pro-
tease inhibitor UTI reduced experimental tumor invasion and
metastasis of ovarian carcinoma and choriocarcinoma cells
[23]. All of these animal experiments provide ‘proof of prin-
ciple’ for the use of antagonists of uPA/uPAR-interaction in
tumor inhibition. However, the application of large recombi-
nant proteins for treatment of patients appears rather di⁄cult
and depends on sophisticated, e.g. viral, delivery systems [18].
Therefore, others and we have concentrated on the develop-
ment of small, synthetic competitive or non-competitive pep-
tide antagonists [7^11,24^27].
Previously, we have demonstrated in in vitro assays that
synthetic uPA-derived peptides such as cyclo19;31-uPA1931
or its [D-Cys19]-derivative WX-307 e⁄ciently inhibit binding
of uPA to cell surface-associated uPAR on human tumor cells
[7]. These peptides not only block binding of uPA to uPAR
but are also capable to displace uPAR-bound uPA from the
cell surface and to inhibit uPA-mediated, tumor cell-associ-
ated plasminogen activation and ¢brin degradation [7,8]. Re-
duction of the ring-size and D-amino acid scanning led to
WX-360 (cyclo21;29[D-Cys21]-uPA2130[S21C;H29C]), display-
ing a ¢ve-fold higher a⁄nity towards uPAR than WX-307
(IC50W40 nM versus W200 nM) [9,10]. Furthermore, as
WX-360 harbors a lysine residue (K23) and, thus, a target
site for serine proteases such as plasmin, K23 was replaced
by the non-protein amino acid norleucine (WX-360-Nle).
This derivative still displays high binding a⁄nity (IC50W70
nM). Stability testing showed that both WX-360 and WX-
360-Nle, respectively, were highly resistant to proteolytic deg-
radation in human and rodent plasma or serum whereas other
uPA-derived peptides lacking a non-natural D-amino acid
(such as cyclo19;31-uPA1632) were signi¢cantly less stable:
after 1 h incubation at 37‡C, peptide cyclo19;31-uPA1632 was
completely degraded, whereas WX-360 and WX-360-Nle, re-
spectively, were stable over a period of 24 h. After incubation
with high amounts of plasmin (5 Wg of peptide were incubated
with 0.01 U [W4 Wg] of plasmin at 37‡C), however, WX-360
was degraded, whereas WX-360-Nle was completely resistant
to proteolysis [11].
In the present study, we demonstrate that treatment of tu-
mor-bearing mice with small, synthetic, cyclic, competitive
uPAR-binding site-derived uPA antagonists results in a highly
signi¢cant reduction of tumor burden and also dissemination
in the peritoneal cavity in vivo. In the nude mouse model, we
used human ovarian cancer cells, which typically induce a
large primary tumor and abundant intraperitoneal metastases
[13]. The results are in line with those of a previous study, in
which administration of a synthetic non-competitive peptidic
antagonist of uPA/uPAR interaction, the so-called AV 6-peptide
(75 mg per kg per day; two intraperitoneal injections per day),
inhibited tumor growth signi¢cantly and suppressed the devel-
opment of lymph node metastases in several breast cancer
models [26].
Substitution of K23 in WX-360 with the non-protein amino
acid norleucine did not signi¢cantly alter the biological e⁄-
Fig. 3. E¡ect of synthetic cyclic competitive uPA-derived peptide
antagonists on primary tumor growth and spread. After inoculation
of OV-MZ-6#8-BAG cells, nude mice were treated with either WX-
360, WX-360-Nle (in each case 20 mg/kg/day), or vehicle for 37
days (single intraperitoneal injection per day). The groups were
compared to each other with respect to tumor burden (given as the
ratio of tumor weight over total situs weight) (A) and organ weight
(B). The box plot indicates the 25th and 75th percentiles, the verti-
cal bars mark the 10th and 90th percentiles, respectively. The me-
dian value is indicated by a bold bar. n.s., not signi¢cant.
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cacy of the peptide, although WX-360-Nle displays a further
increased proteolytic stability as compared to its parent pep-
tide WX-360. Compared to WX-360, WX-360-Nle is distinctly
less soluble in aqueous solutions, because the exchange of the
positively charged lysine side chain by the aliphatic norleucine
side chain results in a zero net charge of the peptide. Interest-
ingly, some mice developed an excitable behavior during the
treatment with WX-360-Nle, which was characterized by
heavy struggle against injections and an aggressive behavior
beginning after the ¢rst week of administration. It is tempting
to speculate that the lower solubility of WX-360-Nle may give
rise to intraperitoneal peptidic precipitates. The behavioral
changes in the mice receiving WX-360-Nle may be related to
a poor tolerability of such intraperitoneal precipitates.
In conclusion, we have demonstrated that small synthetic
cyclic competitive uPA peptide-antagonists can e¡ectively re-
duce tumor growth and spread of human ovarian cancer cells
in a mouse tumor model. These results strongly suggest that
the peptides WX-360 and WX-360-Nle are su⁄ciently stable
within the peritoneal cavity to e⁄ciently interfere with uPA/
uPAR-interaction on the tumor cells. Since ovarian cancer is a
disease, that spreads throughout the abdominal cavity, puta-
tive new uPAR-directed drugs could be administered intra-
peritoneally. Thus, WX-360 and WX-360-Nle represent prom-
ising new compounds to reduce tumor burden and
dissemination of human ovarian carcinomas.
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